ERBB2 and breast carcinoma: Therefore, a follow-up trial was conducted to explore the clinical utility of [68Ga]Ga-ABY-025 PET imaging in 16 breast cancer patients, including both HER2-positive and HER2-negative patients as defined by biopsy [36].